The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes.
FEBS J
; 288(17): 5042-5054, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1295003
ABSTRACT
The COVID-19 pandemic has highlighted the vulnerability of people with diabetes mellitus (DM) to respiratory viral infections. Despite the short history of COVID-19, various studies have shown that patients with DM are more likely to have increased hospitalisation and mortality rates as compared to patients without. At present, the mechanisms underlying this susceptibility are unclear. However, prior studies show that the course of COVID-19 disease is linked to the efficacy of the host's T-cell responses. Healthy individuals who can elicit a robust T-cell response are more likely to limit the severity of COVID-19. Here, we investigate the hypothesis that an impaired T-cell response in patients with type 2 diabetes mellitus (T2DM) drives the severity of COVID-19 in this patient population. While there is currently a limited amount of information that specifically addresses T-cell responses in COVID-19 patients with T2DM, there is a wealth of evidence from other infectious diseases that T-cell immunity is impaired in patients with T2DM. The reasons for this are likely multifactorial, including the presence of hyperglycaemia, glycaemic variability and metformin use. This review emphasises the need for further research into T-cell responses of COVID-19 patients with T2DM in order to better inform our response to COVID-19 and future disease outbreaks.
Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Diabetes Mellitus Tipo 2
/
COVID-19
/
Hiperglicemia
Tipo de estudo:
Estudo prognóstico
Tópicos:
Covid persistente
Limite:
Humanos
Idioma:
Inglês
Revista:
FEBS J
Assunto da revista:
Bioquímica
Ano de publicação:
2021
Tipo de documento:
Artigo
País de afiliação:
Febs.16105
Similares
MEDLINE
...
LILACS
LIS